Multiple myeloma (MM) is the second most common hematological malignancy of plasma
cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the …

Multiple myeloma (MM) is an incurable hematologic malignancy. Most MM patients are
diagnosed at a late stage because the early symptoms of the disease can be uncertain and …

Nuclear factor-κB (NF-κB) transcription factors play a key role in the pathogenesis of multiple
myeloma (MM). The survival, proliferation and chemoresistance of malignant plasma cells …

The dysregulation of non-coding RNAs (ncRNAs), specifically microRNAs (miRNAs) and
long non-coding RNAs (lncRNAs), leads to the development and advancement of multiple …

Major epigenetic changes are associated with carcinogenesis, including aberrant DNA
methylations and post-translational modifications of histone. Indeed evidence accumulated …

Multiple myeloma (MM) is an incurable hematological disease characterized by the
uncontrolledgrowth of plasma cells primarily in the bone marrow. Although its treatment …

Background. Multiple myeloma (MM) is a clonal plasma cell disorder which still lacks
sufficient prognostic factors. The serine/arginine‐rich splicing factor (SRSF) family serves as …

Histone deacetylases (HDACs) are commonly overexpressed in several types of human
cancers, including prostate cancer (PCa). Histone deacetylase inhibitors (HDACis) are …

Background Multiple myeloma (MM) is a hematological malignancy characterized by the
clonal proliferation of malignant plasma cells within the bone marrow. The disease's …

Multiple myeloma remains an incurable hematological disease originating from the bone
marrow. Many drugs and drug combinations are used to treat multiple myeloma. Although …